Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New heat treatment may cut cancer pain without extra drugs

NCT ID NCT05535894

Symptom relief Sponsor: West Virginia University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a procedure called endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) to treat pain in 19 people with advanced pancreatic cancer that could not be removed by surgery. The goal was to see if zapping the celiac ganglion—a bundle of nerves—could reduce pain and improve quality of life. Researchers measured pain levels, medication use, and well-being before and after the procedure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
radiofrequency ablation of the celiac ganglion
What this could lead to
If it works, this could offer a new way to manage severe pain and reduce the need for strong painkillers in people with advanced pancreatic cancer.
What could go wrong
This was a small, early study with only 19 participants, so results may not apply to everyone. The procedure carries risks like bleeding or infection, and pain relief may not last long.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

19 people

The number who actually took part.

Started

Aug 2022

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with advanced pancreatic cancer who are deemed as non-surgical candidates

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of pancreatic cancer based on clinical, radiological, or pathological assessment; * Referred for abdominal and/or back pain due to pancreatic cancer; * No prior history of RFA; * Cancer pain unresponsive to the WHO 3-step analgesic ladder; * Willingness to consent to participate in the study. Exclusion Criteria: * Patients who are not willing to give informed consent or agree to participate in the study * Surgically resectable pancreatic cancer; * Abdominal pain with etiology other than pancreatic malignancy; * Evidence of concurrent infection; * Patients with irreversible coagulopathy international normalized ratio \>1.5 or platelet count \<50,000/mm3), * Patients with a preliminary diagnosis of adenocarcinoma are not possible established with intraprocedural at EUS-guided FNA.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pancreatic cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pancreatic cancer

Contacts and locations

Locations

  • Shailendra Singh

    Morgantown, West Virginia, 26508, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.